



SPRUSD

Setting **P**riorities & **R**educing
Uncertainties for people with
Skin **D**isease

SPRUSD NEWSLETTER



SPRUSD Away Day November 8th 2011

I am very pleased to say that we didn't have to battle against sub-zero temperatures this year for our annual get together to celebrate the successes of the SPRUSD programme of work.

This year's event was slightly different to previous meetings as the morning was spent in small working groups, but the afternoon was dedicated to sharing and discussing the progress that we have made so far, and our plans for the coming months.

Thanks to a great turn-out and keen audience participation, the day was a great opportunity to catch up and share reflections together. Thanks to all of you who attended and contributed on the day.



Eczema Priority Setting Partnership (PSP)

We have had a phenomenal response to our Eczema Priority Setting Partnership and received over 1,100 treatment uncertainties from patients and health professionals.

The team have now processed these responses, and a list of the most frequently asked questions was re-circulated for a second round of voting in early December. Again we had a great response (500 people voted) and we now have a list of the 14 most important areas for future research: 4 are shared priorities; 5 are patients' priorities, and 5 are health professionals' priorities.

These will now be discussed at a research prioritisation workshop in London on January 9th, 2012.

You can find more information about the partnership through the 'HOME' website at www.homeforeczema.org, or by contacting Tessa Clarke, Senior Clinical Trials Development Manager: Tessa.Clarke@nottingham.ac.uk



Recent Publications

- Michelle Foisy, Lorne A. Becker, Joanne R. Chalmers, Robert J. Boyle, Eric L. Simpson and Hywel C. Williams; "Mixing with the 'unclean': including non-Cochrane reviews alongside Cochrane reviews in overviews of reviews". Poster presented at the Cochrane Colloquium (19-22 October 2011).
- A systematic review of observational studies of treatments for primary non-metastatic squamous cell carcinoma of the skin – challenges to improve the evidence." Poster presentation at Evidence 2011 conference – London, October 2011

HI-Light trial for Vitiligo



This study will be the first double-blind RCT on home light therapy in the UK. The **HI-Light** (Home Intervention of **L**ight therapy) trial for vitiligo is a small pilot trial comparing hand-held light therapy (NB-UVB) devices with placebo devices. These devices will be used by the participants to treat their vitiligo at home for a period of four months.

The main purpose of the trial is to find out and test various logistics around a future multi-centre RCT of these devices.

Recruitment will take place in Nottingham and Leicester, with additional patients identification centres in Derby, Mansfield and local GP practices.

The trial will start recruiting in mid January 2012.

This study is conducted as part of Dr Viktoria Eleftheriadou PhD on vitiligo. If you would like to find out more please contact Viktoria on



Viktoria.eleftheriadou@nottingham.ac.uk

CEBD welcomes Dr Akerke Baibergenova

We were delighted to host a 3-week research elective for Ake Baibergenova over the summer of 2012. Ake worked closely with Helen, Kim and Hywel to complete an excellent paper on outcome reporting bias in eczema trials, and was a perfect example of what can be achieved using the GREAT database.

"CEBD was a great place to have my research elective. Even within my short 3 week visit I have learned a lot through working on a stimulating research project. The team was welcoming, friendly and supportive." Dr Akerke Baibergenova, Toronto, Canada



Contact Details



Barbara Maston, Research Administration Assistant, Centre of Evidence Based Dermatology, University of Nottingham, Room A103, Kings Meadow Campus, Lenton Lane, Nottingham, NG7 2NR. Telephone 0115 8468631 e-mail Barbara.maston@nottingham.ac.uk

Hope you all have a lovely Christmas and best wishes for a happy and bright 2012.

The SPRUSD Programme Grant is funded by a National Institute for Health Research